Pfizer hands another asset to Roivant
Does yesterday’s deal with Roivant mean the pharma giant is cooling on TL1A targeting? And what about Prometheus?
The next cell therapy move takes Astra into neoantigens
For $200m Astrazeneca buys Neogene, and Alaunos’s long-suffering investors can just look on.
Merck opens its mind to epigenetics with Imago buy
The purchase sets up another showdown with the group’s old rival, Bristol Myers Squibb, in LSD1 inhibition.
Lantheus has three shots on goal to challenge Novartis
Two days after tying up with Point the company outlines plans to dominate PSMA-based prostate cancer screening and treatment.
Lantheus gets to the Point in therapeutics
Lantheus goes further into radioligand therapeutics, but the market thinks its latest push shortchanges Point Biopharma.
